1. Maximizing Disease-Free Survival in Early-Stage HER2-Positive Breast Cancer

3. Introduction to HER2+ Early Breast Cancer

4. Newer HER2-Targeted Agents Used in Early Breast Cancer: Pertuzumab

5. Use of Pertuzumab in Adjuvant Setting

6. Considerations with Pertuzumab

7. Newer HER2-Targeted Agents Used in Early Breast Cancer: Neratinib

8. Subset Analysis in ExteNET Trial

9. Neratinib-Associated Diarrhea

10. Newer HER2-Targeted Agents Used in Early Breast Cancer: Ado-Trastuzumab Emtansine (T-DM1)

11. Toxicities Associated with T-DM1

12. Options for High Risk Patients With HER2+ Early BC

13. Is De-Escalating Treatment Ever an Option?

14. Incorporating Novel Agents into Practice: Adjuvant Therapy Guidelines

15. Patient Education Tips with HER2-Targeted Therapies for Early BC

16. Managing Side Effects Associated With HER2-Targeted Agents

17. Implementing a Patient-Centered Approach

18. Multidisciplinary Team Involved in Care of Patients With Higher-Risk Early Breast Cancer

19. Management and Education for Patients Receiving HER2-Targeted Therapies for Early BC

20. Moving Towards Personalized Therapy for HER2+ Breast Cancer

21. Abbreviations